Bleeding tendency caused by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide

Br J Haematol. 1988 Mar;68(3):313-9. doi: 10.1111/j.1365-2141.1988.tb04208.x.

Abstract

A case exhibiting bleeding tendency caused by an acquired inhibitor to factor XIII is reported. The patient, a hitherto healthy 87-year-old Japanese man, presented with a massive subcutaneous bleeding, leading to severe anaemia. The routine coagulation study was normal except for a decreased plasma factor XIII level, which was 3% of the control level by the dansylcadaverine incorporation assay. An inhibitor of factor XIII was demonstrated to be present in the IgG fraction of the patient's plasma; by immunoblotting this inhibitor was shown to bind specifically the a and a' subunits of factor XIII. The IgG fraction suppressed the transglutaminase activity of activated factor XIII, but did not inhibit the molecular transformation of subunit a to a' in the activation process. Massive infusion of plasma and factor XIII concentrate was effective for controlling the bleeding temporarily. In the long-term prednisolone was ineffective for suppressing the plasma inhibitor level and bleeding episodes recurred. A small daily dose (50 mg) of cyclophosphamide, however, effectively decreased the inhibitor level and controlled bleeding.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cyclophosphamide / therapeutic use*
  • Factor VIIIa
  • Factor XIII / antagonists & inhibitors*
  • Factor XIII / metabolism
  • Hemorrhagic Disorders / drug therapy*
  • Humans
  • Immunoglobulin G / immunology*
  • Immunoglobulin G / metabolism
  • Male

Substances

  • Immunoglobulin G
  • Factor VIIIa
  • Cyclophosphamide
  • Factor XIII